Listed are current opportunities for patient groups, clinician groups, drug plans, and cancer agencies to provide input or feedback on drugs being assessed within the reimbursement review process.
At CADTH, input is information, insight, or advice given to CADTH to contribute to a review. Feedback is a response to a prepared proposal, review report, or draft recommendation.
Therapeutic Area: Primary hyperlipidemia Draft recommendations posted for stakeholder feedback: May 16, 2024 End of feedback period: May 31, 2024 Draft Recommendation